J Clin Oncol. 2004 Apr 1;22(7):1180-7. Epub 2004 Feb 23.% J- o/ b$ H; J$ n3 F! O
, L8 z, Y3 F7 {) }) w h- P
Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598.
; p0 b; i( r$ c9 v2 I7 h5 b' o& _ b( ?0 h
Langer CJ, Stephenson P, Thor A, Vangel M, Johnson DH; Eastern Cooperative Oncology Group Study 2598.9 H( g5 i- _ I2 e0 ?1 D# S
; ^# T7 U, Y/ s* T" d1 _ m" ~: h' J( u1 Q
Source
! H1 W. a5 Z* P2 w( A) [/ U7 {- j. [9 A& g5 Z6 k% y
Fox Chase Cancer Center, Philadelphia, PA 19111, USA. CJ_Langer@fccc.edu
2 X! _# d3 m% x( D) ~8 u0 ~0 P7 @2 o0 I. m7 D. J3 \1 W% H; y
0 ]7 x" G) a! n: b2 y
Abstract. \+ w: z# r7 X) \. _; H
6 N9 y6 p7 W0 V- R& J4 t* M
PURPOSE: , r3 u1 x! H" c+ i
: F$ T% s2 I" i
Multiple non-small-cell lung cancer (NSCLC) cell lines and 20% to 50% of pathologic specimens express HER-2/neu, the target of trastuzumab, and HER-2/neu expression has proven to be an independent, unfavorable prognostic factor in resected patients with NSCLC. Trastuzumab, in vitro, has demonstrated growth-inhibiting synergy with platinating agents, and additivity with paclitaxel. The Eastern Cooperative Oncology Group therefore launched a phase II study evaluating combination carboplatin, paclitaxel, and trastuzumab in patients with advanced NSCLC.
! L! E1 Y0 P4 ]* c5 P0 g2 R
, s0 }* E, c o- fMATERIALS AND METHODS:
: R) |* U% A7 C# x) Q; h/ E) }5 t8 o H0 \9 ?
Eligibility stipulated the following: measurable tumor, HER-2/neu positivity (1+ to 3+ by Herceptest [Dako Corp, Carpinteria, CA], confirmed by central review), Eastern Cooperative Oncology Group PS 0 to 1, adequate marrow, hepatic and renal function, and left ventricular ejection fraction >or= 45%. Patients received paclitaxel 225 mg/m(2)/3 hours, and carboplatin (area under the curve, 6) every 3 weeks, and trastuzumab 4 mg/kg intravenously on day 1, then 2 mg/kg weekly for <or= 1 year.) O0 @# X/ Q1 |' |0 N
) T: L0 W3 I/ Z( y. P
RESULTS: 7 h0 I2 |2 p- Q# ?7 y7 G
: A0 l- b, ?: K- b) c! NBetween August 1999 and May 2000, 139 patients were screened; seven specimens (5%) were indeterminate. Fifty patients (36%) were HER-2/neu negative, 38 (27%) were HER-2/neu 1+, 31 (22%) were 2+, and 13 (9%) were 3+. Fifty-six patients were enrolled; 53 were eligible (22 [42%] were 1+, 23 (43%) were 2+, and eight (15%) were 3+). Thirteen (24.5%) of 52 assessable patients (95% CI, 13.8 to 38.3) responded. The incidence of grade >or= 3 neutropenia and thrombocytopenia was 57% (34%) and 16% (2%), respectively. Asymptomatic grade <or= 2 reduction in left ventricular ejection fraction occurred in 7%. Other nonhematologic toxicities, including nausea, fatigue, arthralgias, and peripheral sensory neuropathy, were mild to moderate and matched those expected with carboplatin and paclitaxel alone. Eighteen patients (35%) received maintenance trastuzumab. Median progression-free survival was 3.3 months; median survival was 10.1 months, and 1-year survival rate was 42%.
+ S% d& e G1 L* X
0 K( X8 s% v1 ZCONCLUSION: 3 G; V, W. U2 ?+ r B4 l
4 B: v s' P2 [
Combination paclitaxel, carboplatin, and trastuzumab is feasible. Toxicity appears no worse than cytotoxic therapy alone. Overall survival is similar to historical data using carboplatin and paclitaxel alone. However, patients with 3+ HER-2/neu expression did well in contrast to historical data suggesting potential benefit for trastuzumab in this rare subset of NSCLC. Critical assessment of trastuzumab's role in advanced NSCLC will require phase III trials.
$ o& B' X0 v: D |
显身卡
